ATE143019T1 - Xanthin derivate - Google Patents

Xanthin derivate

Info

Publication number
ATE143019T1
ATE143019T1 AT93120842T AT93120842T ATE143019T1 AT E143019 T1 ATE143019 T1 AT E143019T1 AT 93120842 T AT93120842 T AT 93120842T AT 93120842 T AT93120842 T AT 93120842T AT E143019 T1 ATE143019 T1 AT E143019T1
Authority
AT
Austria
Prior art keywords
lower alkyl
independently represent
chem
represent hydrogen
hydroxy
Prior art date
Application number
AT93120842T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Nobuaki Koike
Hiroshi Kase
Joji Nakamura
Shizuo Shiozaki
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE143019T1 publication Critical patent/ATE143019T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93120842T 1992-12-24 1993-12-23 Xanthin derivate ATE143019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34411692 1992-12-24

Publications (1)

Publication Number Publication Date
ATE143019T1 true ATE143019T1 (de) 1996-10-15

Family

ID=18366763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93120842T ATE143019T1 (de) 1992-12-24 1993-12-23 Xanthin derivate

Country Status (6)

Country Link
US (1) US5670498A (de)
EP (1) EP0607607B1 (de)
AT (1) ATE143019T1 (de)
CA (1) CA2112031A1 (de)
DE (1) DE69304883T2 (de)
NO (1) NO300925B1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161011A1 (en) * 1994-02-23 1995-08-31 Fumio Suzuki Xanthine derivatives
EP1666041A3 (de) * 1997-09-05 2008-04-02 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivate zur Behandlung neurodegenerativer Störungen
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
AU7962000A (en) * 1999-10-29 2001-05-14 Kyowa Hakko Kogyo Co. Ltd. Us0027324for eating disorders
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
TWI346114B (en) 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
EP2526949B1 (de) * 2004-01-28 2015-03-04 Kyowa Hakko Kirin Co., Ltd. Mittel zur Behandlung von Migräne
RU2007114908A (ru) 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
KR20080090491A (ko) 2006-02-03 2008-10-08 씨브이 쎄러퓨틱스, 인코포레이티드 A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
CN110981876B (zh) * 2018-12-21 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
AU2021235803A1 (en) 2020-03-10 2022-09-29 Marvel Biotechnology Purine compounds for treating disorders
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法
US20250353849A1 (en) * 2021-12-03 2025-11-20 Marvel Biotechnology Purine compounds for treating disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
WO1992006976A1 (en) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative

Also Published As

Publication number Publication date
NO934792L (no) 1994-06-27
EP0607607B1 (de) 1996-09-18
CA2112031A1 (en) 1994-06-25
NO934792D0 (no) 1993-12-23
US5670498A (en) 1997-09-23
NO300925B1 (no) 1997-08-18
EP0607607A1 (de) 1994-07-27
DE69304883D1 (de) 1996-10-24
DE69304883T2 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
DE69304883D1 (de) Xanthin Derivate
DE69418704D1 (de) Anthranilsäure derivate
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
PL292101A1 (en) Method of obtaining novel derivatives of cyclopentylpurine and cyclopentylpyrimidine
ATE138921T1 (de) Xanthinderivate
PT87183A (pt) Procede de preparation de derives d:aryl-heteroaryl carbinol avec activite analgesique
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
EP1110961A4 (de) Sauerstoffhaltige heterocyclische verbindungen
ATE252074T1 (de) Phenylalkylcarbonsäure-derivate
DE3776044D1 (de) Pyridazinon-derivate.
NO911004D0 (no) (benzhydryloksyetylpiperidyl)alifatiske syrederivater og anvendelse derav.
SE8901060D0 (sv) New compounds
ATE134607T1 (de) Tetrahydronaphtalenderivate, ihre herstellung und ihre therapeutische verwendung
PT87954A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico
ATE25519T1 (de) Benzo(f)chinolinderivate.
HU9202849D0 (en) Method for producing n,n',n-trisubstituted- 5-bis-amino-methylene-1,3-dioxane-4,6-dione derivatives and pharmaceutical preparatives containing them
ATE268769T1 (de) Pyrimidinderivate mit antitumor-wirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties